Zura Bio Limited

NASDAQ:ZURA

Biotechnology

Healthcare
$0.97 +1.93%

+$0.07 today

Market cap
$92.96M
Beta
0.03
P/E (TTM)
-5.5
EPS (TTM)
-$0.67
52W Low $1.00High $7.44

Volume 3.02M

Average 0.75M

ZURA Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Zura Bio LimitedNASDAQ: ZURA

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses dips below year-ago levels

Q1 FY2026 other income / expenses of $1.28M fell 29.6% year over year, behind the +52.8% change in trailing-twelve-month other income / expenses. Sequentially, it rose 3.2% from the prior quarter.

Context

  • Other income / expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -29.6% toward the trailing-twelve-month pace of +52.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.28M+3.2% QoQ
Last fiscal yearDec 2025
$6.6M+136.8% YoY
LTMMar 2026
$6.06M+52.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.6%——
1 year+136.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
6.6M USD
Year-over-year change
+136.8%
4-year CAGR
-8.7%

Other Income / Expenses vs competitors

How ZURA compares with its peers on the latest reported figures

  • ZURA's LTM Mar 2026 other income / expenses of $6.06M is the 4th highest of the 11 companies compared; the peer median is $5.33M.
  • Its year-over-year change of +52.8% is the 2nd highest of 11, against a peer median of -29.0%.
ZURA Competitors Peer median
Other Income / Expenses for ZURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$10.54M -22.0%—23.2%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$7.16M +37.9%+80.4%10.1%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$7.03M -30.0%+11.2%—
ZURAZura Bio LimitedLTM Mar 2026$6.06M +52.8%——
PYXSPyxis Oncology, Inc.LTM Mar 2026$5.52M -41.1%+30.8%39.8%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$5.44M -67.9%-1.8%19.3%
SGMTSagimet Biosciences Inc.LTM Mar 2026$5.23M -38.1%+119.1%—
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$4.85M +44.2%——
IMRXImmuneering CorporationLTM Mar 2026$4.79M +95.0%+39.6%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.85M -27.9%+11.8%1268.0%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$1.51M -146.9%+2.8%2.2%
Peer median (excluding ZURA) $5.33M-29.0%+21.3%21.3%

Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development023.69M44M24.4M42.08M
Selling, General & Admin1.09M3.47M18.64M30.79M33.16M
Operating Expenses1.09M27.16M62.64M55.19M75.25M
Depreciation & Amortization0009K49K
EBITDA8.42M(27.33M)(60.56M)(52.39M)(68.6M)
EBITDA Margin—————
Operating Income(1.09M)(27.16M)(62.64M)(55.19M)(75.25M)
Operating Margin—————
Interest Income23.48K5702.19M8M6.34M
Interest Expense00000
Other Income / Expenses9.51M(171K)2.08M2.79M6.6M
Income Before Tax8.42M(27.33M)(60.56M)(52.4M)(68.65M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income8.42M(25.74M)(60.36M)(52.4M)(68.65M)
Net Margin—————
EPS (Basic)0.400.21(2.09)(0.60)(1.06)
EPS (Diluted)0.400.21(2.09)(0.60)(1.06)
Weighted Avg Shares17.25M17.25M33.06M75.07M94.16M
Weighted Avg Shares (Diluted)17.25M17.25M33.06M75.07M94.16M

Zura Bio Limited

NASDAQ:ZURA

Intrinsic Alpha fair value

Locked

Current Price

$0.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.